Pancreatic Cancer Research

ResearcherUniversity of DelawareActive in the last 2 years

Jonathan Robert Brody

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3680-3270; OpenAlex author ID A5079398934; NIH RePORTER profile ID 8439029. Sources: funder_awards.

Their work

Papers
77 (first author 3, last author 30)
Trials
0
Grants
9
Labs led
2
Collaborators
172
Papers, trials and grants by year

2010: 1 grant · 2011: 2 papers · 2012: 5 papers · 2013: 4 papers · 2014: 2 papers · 2015: 5 papers, 2 grants · 2016: 7 papers · 2017: 5 papers · 2018: 9 papers · 2019: 6 papers · 2020: 3 papers · 2021: 3 papers, 1 grant · 2022: 4 papers · 2023: 5 papers, 2 grants · 2024: 4 papers · 2025: 8 papers, 1 grant · 2026: 5 papers, 2 grants

Papers 50 of 77

  1. Impaired Adipose Anabolism in Pancreatic Cancer Cachexia Is Reversed by HuR Inhibition. Co-author DOI 10.1002/jcsm.70253↗
  2. Addressing pancreatic cancer disparities in Oregon's Native American population via tribally responsive research systems with the confederated tribes of warm s… Co-author DOI 10.1007/s10552-026-02148-x↗
  3. Schedule-dependent efficacy of gemcitabine and RAS(ON) inhibition in orthotopic pancreatic cancer: implications for clinical trial design. Last author DOI 10.1016/j.canlet.2026.218864↗
  4. The Posttranscriptional Regulator HuR Promotes Immune Evasion in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1136/jitc-2025-sitc2025.1250↗
  5. Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies. Co-author DOI 10.1158/2767-9764.crc-25-0338↗
  6. Targeting BARD1 suppresses a Myc-dependent transcriptional program and tumor growth in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.neo.2025.101152↗
  7. Ongoing replication stress tolerance and clonal T cell responses distinguish liver and lung recurrence and outcomes in pancreatic cancer. Co-author DOI 10.1038/s43018-024-00881-3↗
  8. Challenges and caveats in manipulating extracellular vesicle secretion from pancreatic cancer cells. First author DOI 10.1080/15384047.2025.2569946↗
  9. Post-transcriptional regulator HuR promotes immune evasion in pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2025.02.07.632847↗
  10. Myc and Kras cooperate in adult acinar cells to drive phenotypic heterogeneity, metastasis, and therapeutic resistance in a novel pancreatic cancer mouse model Co-author DOI 10.1101/2025.07.14.664767↗
  11. HuR-Regulated Extracellular Vesicles Promote Endothelial Cell Remodeling in Pancreatic Cancer. Last author DOI 10.1158/2767-9764.crc-25-0355↗
  12. MicroCT Enables Simultaneous Longitudinal Tracking of Murine Pancreatic Cancer Progression and Cachexia. Co-author DOI 10.1158/2767-9764.crc-25-0414↗
  13. A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathway Co-author DOI 10.64898/2025.12.12.693851↗
  14. CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer. Co-author DOI 10.1080/14796694.2024.2395235↗
  15. The polymeric fluoropyrimidine CF10 overcomes limitations of 5-FU in pancreatic ductal adenocarcinoma cells through increased replication stress. Last author DOI 10.1080/15384047.2024.2421584↗
  16. IDH1 Inhibition Potentiates Chemotherapy Efficacy in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-23-1895↗
  17. The Pivotal Role of Germline BRCA2 Pathogenic Variants in "Apparently Sporadic" Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-24-2730↗
  18. Strategies for the Management of Patients with Pancreatic Cancer with PARP Inhibitors. Last author DOI 10.1007/978-3-031-30065-3_8↗
  19. Increased glucose availability sensitizes pancreatic cancer to chemotherapy. Co-author DOI 10.1038/s41467-023-38921-8↗
  20. Deletion of the mRNA stability factor ELAVL1 (HuR) in pancreatic cancer cells disrupts the tumor microenvironment integrity. Last author DOI 10.1093/narcan/zcad016↗
  21. Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancrea… Co-author DOI 10.1136/bmjopen-2023-073839↗
  22. Micelle-Formulated Juglone Effectively Targets Pancreatic Cancer and Remodels the Tumor Microenvironment. Co-author DOI 10.3390/pharmaceutics15122651↗
  23. Disparities in pancreatic cancer care and research in Native Americans: Righting a history of wrongs. Co-author DOI 10.1002/cncr.34118↗
  24. The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1128/mcb.00018-22↗
  25. Liver Endothelium Microenvironment Promotes HER3-mediated Cell Growth in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.26502/jcsct.5079182↗
  26. HuR Plays a Role in Double-Strand Break Repair in Pancreatic Cancer Cells and Regulates Functional BRCA1-Associated-Ring-Domain-1(BARD1) Isoforms. Last author DOI 10.3390/cancers14071848↗
  27. Selecting the optimal parameters for sonoporation of pancreatic cancer in a pre-clinical model. Co-author DOI 10.1080/15384047.2021.1881026↗
  28. The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria. Last author DOI 10.1158/1535-7163.mct-20-0652↗
  29. AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy with PARG Inhibition. Last author DOI 10.1158/1541-7786.mcr-20-0985↗
  30. Effect of Hypercapnia, an Element of Obstructive Respiratory Disorder, on Pancreatic Cancer Chemoresistance and Progression. Last author DOI 10.1016/j.jamcollsurg.2019.12.033↗
  31. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor … Co-author DOI 10.1016/s1470-2045(20)30074-7↗
  32. A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-20-1301↗
  33. Evaluation of Post-transcriptional Gene Regulation in Pancreatic Cancer Cells: Studying RNA Binding Proteins and Their mRNA Targets. Last author DOI 10.1007/978-1-4939-8879-2_22↗
  34. A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1089/pancan.2019.0003↗
  35. Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-18-3645↗
  36. ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications. Co-author DOI 10.1158/1535-7163.mct-19-0208↗
  37. Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition. Last author DOI 10.1158/1541-7786.mcr-19-0589↗
  38. Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program. Co-author DOI 10.1200/po.19.00115↗
  39. Complex HuR function in pancreatic cancer cells. Co-author DOI 10.1002/wrna.1469↗
  40. A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2. Last author DOI 10.1016/j.jamcollsurg.2017.12.052↗
  41. Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer. Co-author DOI 10.1080/15384047.2016.1210743↗
  42. Genetic Drivers of Pancreatic Cancer Are Identical Between the Primary Tumor and a Secondary Lesion in a Long-Term (>5 Years) Survivor After a Whipple Procedur… Co-author DOI 10.1089/pancan.2018.0015↗
  43. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Tria… Last author DOI 10.1097/sla.0000000000002088↗
  44. Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative. Co-author DOI 10.1158/1078-0432.ccr-18-0531↗
  45. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-18-0349↗
  46. Metabolic Dependencies in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2018.00617↗
  47. Corrigendum: Metabolic Dependencies in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2018.00672↗
  48. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. Last author DOI 10.1038/bjc.2017.40↗
  49. Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells. Co-author DOI 10.1158/0008-5472.can-17-0015↗
  50. Anaplastic Lymphoma Kinase Rearrangement and Response to Crizotinib in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/po.17.00016↗

Grants 9

  1. Optimizing anti-wild-type IDH1 therapy in pancreatic cancer R01CA287672↗
  2. Leveraging high glucose to prevent pancreatic cancer progression R01CA305024↗
  3. An atlas of pancreatic tumorigenesis in the context of altered DNA repair occurring in high-risk individuals U01CA294548↗
  4. Developing a patient derived model platform to treat BRCA1/2-mutant pancreatic cancers R21CA263996↗
  5. Comparative analysis between patient-derived models of pancreatic ductal adenocarcinomas and matched tumor specimens U01CA224012↗
  6. Targeting HuR to improve a synthetic lethal therapy for pancreatic cancer R01CA212600↗
  7. Developing an algorithm for Molecular Tailored Therapy AWARD pancan:2015-jonathan-brody-phd-developing-an-algorithm-for-molecular-ta
  8. Utilizing HuR to optimize the treatment of pancreatic cancer R21CA182692↗
  9. HuR is a Predictive and Prognostic Marker in Pancreatic Cancer AWARD pancan:2010-jonathan-brody-phd-hur-is-a-predictive-and-prognostic-marke

Closest collaborators

The 25 strongest of 172 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rosalie C. Sears · 16 shared papers, 3 shared grants, 2022–2026 · strength 5.08
  2. Jordan Michael Winter · 24 shared papers, 2 shared grants, 2012–2026 · strength 4.34
  3. Charles J. Yeo · 30 shared papers, 2011–2025 · strength 2.15
  4. Michael Jon Pishvaian · 19 shared papers, 2015–2026 · strength 1.92
  5. Jennifer M. Finan · 7 shared papers, 2023–2026 · strength 1.80
  6. Lisa M. Coussens · 6 shared papers, 1 shared grant, 2023–2026 · strength 1.67
  7. Grace A. McCarthy · 9 shared papers, 2019–2026 · strength 1.45
  8. Aditi Jain · 9 shared papers, 2019–2025 · strength 1.17
  9. Avinoam Nevler · 9 shared papers, 2017–2025 · strength 1.05
  10. Katie E. Blise · 5 shared papers, 2025–2026 · strength 0.98
  11. Kevin Hawthorne · 5 shared papers, 2025–2026 · strength 0.98
  12. Ali Vaziri Gohar · 7 shared papers, 2017–2026 · strength 0.97
  13. Brett C. Sheppard · 5 shared papers, 2022–2026 · strength 0.97
  14. Aaron J. Grossberg · 4 shared papers, 2025–2026 · strength 0.97
  15. Charles D. Lopez · 5 shared papers, 2024–2026 · strength 0.96
  16. Katherine R. Pelz · 4 shared papers, 2025–2026 · strength 0.92
  17. Laura DeLong Wood · 1 shared paper, 1 shared grant, 2025 · strength 0.90
  18. Christopher William Schultz · 8 shared papers, 2019–2023 · strength 0.86
  19. Yifei Guo · 4 shared papers, 2023–2026 · strength 0.81
  20. Patrick Joseph Worth · 4 shared papers, 2025 · strength 0.74
  21. Elana Judith Fertig · 1 shared grant, 2025 · strength 0.73
  22. Adel Kardosh · 4 shared papers, 2024–2026 · strength 0.73
  23. Emek Demir · 1 shared paper, 1 shared grant, 2023–2025 · strength 0.69
  24. Mehrdad Zarei · 4 shared papers, 2022–2026 · strength 0.69
  25. Omid Hajihassani · 4 shared papers, 2022–2026 · strength 0.69

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.